Opinion|Videos|August 12, 2024
Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
Author(s)Paolo Tarantino, MD
Dr. Tarantino discuss long-term safety and efficacy findings from the APHINITY trial's 8-year follow-up with pertuzumab, and insights from the NeoSphere study's impact on treatment strategies based on efficacy and safety data.
Episodes in this series
Video content above is prompted by the following:
- Please provide some background on APHINITY 8-Year follow up data evaluating pertuzumab with adjuvant trastuzumab and chemotherapy in early HER2+ breast cancer.
- With a median follow up of 8.4 years, what are your impressions of the long-term safety and efficacy profile of pertuzumab?
- Is the IDFS benefit observed with pertuzumab sustained over the extended follow-up period?
- Does the addition of pertuzumab have a positive impact on quality of life for patients with HER2-positive early breast cancer, beyond just extending IDFS?
- Please review the rationale and study design for the NeoSphere pooled analysis study and discuss implications of these data on treatment landscape.
- Which treatment combinations were investigated and how did efficacy outcomes vary between the treatment arms? What are your impressions of these data?
- How did tumor size, node involvement, or biomarker positivity affect efficacy outcomes?
- What are your impressions of the safety data?
Related Content
Advertisement
